;PMID: 3240323
;source_file_943.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..121] = [t:41..121]
;2)section:[e:125..155] = [t:125..155]
;3)section:[e:159..242] = [t:159..242]
;4)sentence:[e:246..336] = [t:246..336]
;5)sentence:[e:337..485] = [t:337..485]
;6)sentence:[e:487..636] = [t:487..636]
;7)sentence:[e:637..944] = [t:637..944]
;8)sentence:[e:945..1131] = [t:945..1131]
;9)sentence:[e:1132..1497] = [t:1132..1497]
;10)section:[e:1501..1545] = [t:1501..1545]

;section 0 Span:0..35
;Biochem Int. 1988 Oct;17(4):755-62.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..11] Int) (.:[11..12] .) (CD:[13..17] 1988)
        (.:[18..25] Oct;17-LRB-) (CD:[25..26] 4) (-RRB-:[26..27] -RRB-)
        (CD:[27..31] :755) (::[31..32] -) (CD:[32..34] 62) (.:[34..35] .)))

;sentence 1 Span:41..121
;Spectral perturbation of human microsomal cytochrome P-450 by flavonoid
;binding.
;[83..99]:cyp450:"cytochrome P-450"
;[103..112]:substance:"flavonoid"
(SENT
  (NP-HLN
    (NP (JJ:[41..49] Spectral) (NN:[50..62] perturbation))
    (PP (IN:[63..65] of)
      (NP (JJ:[66..71] human) (JJ:[72..82] microsomal)
         (NN:[83..93] cytochrome) (NN:[94..99] P-450)))
    (PP (IN:[100..102] by)
      (NP (NN:[103..112] flavonoid) (NN:[113..120] binding)))
    (.:[120..121] .)))

;section 2 Span:125..155
;Moochhala SM, Loke KH, Das NP.
(SEC
  (FRAG (NNP:[125..134] Moochhala) (NNP:[135..137] SM) (,:[137..138] ,)
        (NNP:[139..143] Loke) (NNP:[144..146] KH) (,:[146..147] ,)
        (NNP:[148..151] Das) (NNP:[152..154] NP) (.:[154..155] .)))

;section 3 Span:159..242
;Department of Pharmacology, Faculty of Medicine, National University of 
;Singapore.
(SEC
  (FRAG (NNP:[159..169] Department) (IN:[170..172] of)
        (NNP:[173..185] Pharmacology) (,:[185..186] ,) (NNP:[187..194] Faculty)
        (IN:[195..197] of) (NNP:[198..206] Medicine) (,:[206..207] ,)
        (NNP:[208..216] National) (NNP:[217..227] University) (IN:[228..230] of)
        (NNP:[232..241] Singapore) (.:[241..242] .)))

;sentence 4 Span:246..336
;Aromatase is the cytochrome P-450 complex responsible for oestrogen
;biosynthesis  in vivo.
;[246..255]:cyp450:"Aromatase"
;[263..287]:cyp450:"cytochrome P-450 complex"
;[304..313]:substance:"oestrogen"
(SENT
  (S
    (NP-SBJ (NN:[246..255] Aromatase))
    (VP (VBZ:[256..258] is)
      (NP-PRD
        (NP (DT:[259..262] the)
          
          (NML (NN:[263..273] cytochrome) (NN:[274..279] P-450))
          (NN:[280..287] complex))
        (ADJP (JJ:[288..299] responsible)
          (PP (IN:[300..303] for)
            (NP
              (NP (NN:[304..313] oestrogen) (NN:[314..326] biosynthesis))
              (ADVP (FW:[328..330] in) (FW:[331..335] vivo)))))))
    (.:[335..336] .)))

;sentence 5 Span:337..485
;Inhibitors of this enzyme complex might therefore serve to modulate 
;oestrogen-dependent processes by interfering with the production of
;oestrogens.
;[337..347]:substance:"Inhibitors"
;[356..370]:substance:"enzyme complex"
;[406..415]:substance:"oestrogen"
;[474..484]:substance:"oestrogens"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[337..347] Inhibitors))
      (PP (IN:[348..350] of)
        (NP (DT:[351..355] this)
           (NN:[356..362] enzyme) (NN:[363..370] complex))))
    (VP (MD:[371..376] might)
      (ADVP (RB:[377..386] therefore))
      (VP (VB:[387..392] serve)
        (S
          (NP-SBJ-1 (-NONE-:[392..392] *))
          (VP (TO:[393..395] to)
            (VP (VB:[396..404] modulate)
              (NP
                (ADJP (NN:[406..415] oestrogen) (HYPH:[415..416] -)
                      (JJ:[416..425] dependent))
                (NNS:[426..435] processes))
              (PP-MNR (IN:[436..438] by)
                (S-NOM
                  (NP-SBJ (-NONE-:[438..438] *))
                  (VP (VBG:[439..450] interfering)
                    (PP-CLR (IN:[451..455] with)
                      (NP
                        (NP (DT:[456..459] the) (NN:[460..470] production))
                        (PP (IN:[471..473] of)
                          (NP (NNS:[474..484] oestrogens)))))))))))))
    (.:[484..485] .)))

;sentence 6 Span:487..636
;Thus, these agents may be useful in reproductive processes and in treating 
;oestrogen-dependent disease states such as breast and endometrial cancer.
;[499..505]:substance:"agents"
;[563..572]:substance:"oestrogen"
(SENT
  (S
    (ADVP (RB:[487..491] Thus))
    (,:[491..492] ,)
    (NP-SBJ (DT:[493..498] these) (NNS:[499..505] agents))
    (VP (MD:[506..509] may)
      (VP (VB:[510..512] be)
        (ADJP-PRD (JJ:[513..519] useful))
        (PP
          (PP (IN:[520..522] in)
            (NP (JJ:[523..535] reproductive) (NNS:[536..545] processes)))
          (CC:[546..549] and)
          (PP (IN:[550..552] in)
            (S-NOM
              (NP-SBJ (-NONE-:[552..552] *))
              (VP (VBG:[553..561] treating)
                (NP
                  (NP
                    (ADJP (NN:[563..572] oestrogen) (HYPH:[572..573] -)
                          (JJ:[573..582] dependent))
                    (NN:[583..590] disease) (NNS:[591..597] states))
                  (PP (JJ:[598..602] such) (IN:[603..605] as)
                    (NP
                      (NP (NN:[606..612] breast)
                        (NML-1 (-NONE-:[612..612] *P*)))
                      (CC:[613..616] and)
                      (NP (JJ:[617..628] endometrial)
                        (NML-1 (NN:[629..635] cancer))))))))))))
    (.:[635..636] .)))

;sentence 7 Span:637..944
;We  have demonstrated that inhibitors such as the naturally occurring
;flavonoids  having 5,7-dihydroxy substituents can bind to human placental
;cytochrome P-450  with affinity comparable to their ability to inhibit
;aromatization of  androstenedione and testosterone to oestradiol and
;oestrone, respectively.
;[664..674]:substance:"inhibitors"
;[707..717]:substance:"flavonoids"
;[781..797]:cyp450:"cytochrome P-450"
;[870..885]:substance:"androstenedione"
;[890..902]:substance:"testosterone"
;[906..916]:substance:"oestradiol"
;[921..929]:substance:"oestrone"
(SENT
  (S
    (NP-SBJ (PRP:[637..639] We))
    (VP (VBP:[641..645] have)
      (VP (VBN:[646..658] demonstrated)
        (SBAR (IN:[659..663] that)
          (S
            (NP-SBJ
              (NP (NNS:[664..674] inhibitors))
              (PP (JJ:[675..679] such) (IN:[680..682] as)
                (NP
                  (NP (DT:[683..686] the)
                    (ADJP (RB:[687..696] naturally) (VBG:[697..706] occurring))
                    (NNS:[707..717] flavonoids))
                  (VP (VBG:[719..725] having)
                    (NP (NN:[726..739] 5,7-dihydroxy)
                        (NNS:[740..752] substituents))))))
            (VP (MD:[753..756] can)
              (VP (VB:[757..761] bind)
                (PP-CLR (TO:[762..764] to)
                  (NP (JJ:[765..770] human) (JJ:[771..780] placental)
                     (NN:[781..791] cytochrome) (NN:[792..797] P-450)))
                (PP (IN:[799..803] with)
                  (NP
                    (NP (NN:[804..812] affinity))
                    (ADJP (JJ:[813..823] comparable)
                      (PP (TO:[824..826] to)
                        (NP (PRP$:[827..832] their) (NN:[833..840] ability)
                          (S
                            (NP-SBJ (-NONE-:[840..840] *))
                            (VP (TO:[841..843] to)
                              (VP (VB:[844..851] inhibit)
                                (NP
                                  (NP (NN:[852..865] aromatization))
                                  (PP (IN:[866..868] of)
                                    (NP (NN:[870..885] androstenedione)
                                        (CC:[886..889] and)
                                        (NN:[890..902] testosterone)))
                                  (PP (TO:[903..905] to)
                                    (NP (NN:[906..916] oestradiol)
                                        (CC:[917..920] and)
                                        (NN:[921..929] oestrone))))
                                (,:[929..930] ,)
                                (ADVP (RB:[931..943] respectively))))))))))))))))
    (.:[943..944] .)))

;sentence 8 Span:945..1131
;It  appears that the mechanism of this inhibition requires the flavonoid to
;bind to  the active site of the cytochrome P-450 without prior generation of
;metabolic  intermediate products.
;[1008..1017]:substance:"flavonoid"
;[1053..1069]:cyp450:"cytochrome P-450"
;[1122..1130]:substance:"products"
(SENT
  (S
    (NP-SBJ
      (NP (PRP:[945..947] It))
      (SBAR-1 (-NONE-:[947..947] *EXP*)))
    (VP (VBZ:[949..956] appears)
      (SBAR-1 (IN:[957..961] that)
        (S
          (NP-SBJ
            (NP (DT:[962..965] the) (NN:[966..975] mechanism))
            (PP (IN:[976..978] of)
              (NP (DT:[979..983] this) (NN:[984..994] inhibition))))
          (VP (VBZ:[995..1003] requires)
            (S
              (NP-SBJ (DT:[1004..1007] the) (NN:[1008..1017] flavonoid))
              (VP (TO:[1018..1020] to)
                (VP (VB:[1021..1025] bind)
                  (PP-CLR (TO:[1026..1028] to)
                    (NP
                      (NP (DT:[1030..1033] the) (JJ:[1034..1040] active)
                          (NN:[1041..1045] site))
                      (PP (IN:[1046..1048] of)
                        (NP (DT:[1049..1052] the)
                           (NN:[1053..1063] cytochrome) (NN:[1064..1069] P-450)))))
                  (PP (IN:[1070..1077] without)
                    (NP
                      (NP (JJ:[1078..1083] prior) (NN:[1084..1094] generation))
                      (PP (IN:[1095..1097] of)
                        (NP (JJ:[1098..1107] metabolic)
                            (JJ:[1109..1121] intermediate)
                            (NNS:[1122..1130] products))))))))))))
    (.:[1130..1131] .)))

;sentence 9 Span:1132..1497
;Our data also suggest that the presently known  differences in potency of
;inhibition of cytochrome P-450-mediated aromatization  of steroids by
;different hydroxylated derivatives of 5,7-dihydroxyflavones may  arise from
;their different binding affinity to the enzyme, particularly those  compounds
;hydroxylated in the C3 position in ring C of the flavonoid nucleus.
;[1220..1236]:cyp450:"cytochrome P-450"
;[1264..1272]:substance:"steroids"
;[1299..1310]:substance:"derivatives"
;[1314..1335]:substance:"5,7-dihydroxyflavones"
;[1392..1398]:cyp450:"enzyme"
;[1420..1429]:substance:"compounds"
;[1479..1488]:substance:"flavonoid"
(SENT
  (S
    (NP-SBJ (PRP$:[1132..1135] Our) (NNS:[1136..1140] data))
    (VP
      (ADVP (RB:[1141..1145] also))
      (VBP:[1146..1153] suggest)
      (SBAR (IN:[1154..1158] that)
        (S
          (NP-SBJ
            (NP (DT:[1159..1162] the)
              (ADJP (RB:[1163..1172] presently) (VBN:[1173..1178] known))
              (NNS:[1180..1191] differences))
            (PP (IN:[1192..1194] in)
              (NP
                (NP (NN:[1195..1202] potency))
                (PP (IN:[1203..1205] of)
                  (NP
                    (NP (NN:[1206..1216] inhibition))
                    (PP (IN:[1217..1219] of)
                      (NP
                        (NP
                          (ADJP
                            (NML (NN:[1220..1230] cytochrome)
                                 (NN:[1231..1236] P-450))
                            (HYPH:[1236..1237] -) (VBN:[1237..1245] mediated))
                          (NN:[1246..1259] aromatization))
                        (PP (IN:[1261..1263] of)
                          (NP (NNS:[1264..1272] steroids)))
                        (PP (IN:[1273..1275] by)
                          (NP
                            (NP (JJ:[1276..1285] different)
                                (VBN:[1286..1298] hydroxylated)
                                (NNS:[1299..1310] derivatives))
                            (PP (IN:[1311..1313] of)
                              (NP (NNS:[1314..1335] 5,7-dihydroxyflavones))))))))))))
          (VP (MD:[1336..1339] may)
            (VP (VB:[1341..1346] arise)
              (PP (IN:[1347..1351] from)
                (NP
                  (NP
                    (NP (PRP$:[1352..1357] their) (JJ:[1358..1367] different)
                        (NN:[1368..1375] binding) (NN:[1376..1384] affinity))
                    (PP (TO:[1385..1387] to)
                      (NP (DT:[1388..1391] the) (NN:[1392..1398] enzyme))))
                  (,:[1398..1399] ,)
                  (ADVP (RB:[1400..1412] particularly))
                  (NP
                    (NP (DT:[1413..1418] those) (NNS:[1420..1429] compounds))
                    (VP (VBN:[1430..1442] hydroxylated)
                      (NP (-NONE-:[1442..1442] *))
                      (PP-LOC (IN:[1443..1445] in)
                        (NP
                          (NP (DT:[1446..1449] the) (NN:[1450..1452] C3)
                              (NN:[1453..1461] position))
                          (PP-LOC (IN:[1462..1464] in)
                            (NP
                              (NP (NN:[1465..1469] ring) (NN:[1470..1471] C))
                              (PP (IN:[1472..1474] of)
                                (NP (DT:[1475..1478] the)
                                    (JJ:[1479..1488] flavonoid)
                                    (NN:[1489..1496] nucleus))))))))))))))))
    (.:[1496..1497] .)))

;section 10 Span:1501..1545
;PMID: 3240323 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1501..1505] PMID) (::[1505..1506] :) (CD:[1507..1514] 3240323)
        (-LRB-:[1515..1516] -LSB-) (NNP:[1516..1522] PubMed)
        (HYPH:[1523..1524] -) (NN:[1525..1532] indexed) (IN:[1533..1536] for)
        (NNP:[1537..1544] MEDLINE) (-RRB-:[1544..1545] -RSB-)))
